(Q50559989)

15 March 2018

title

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). (English)

1 reference

15 March 2018

author

Masatoshi Kudo

11

1 reference

15 March 2018

Hiromitsu Kumada

5

object named as

Hiromitsu Kumada

1 reference

15 March 2018

Fumitaka Suzuki

4

object named as

Fumitaka Suzuki

1 reference

15 March 2018

author name string

Izumi Namiki

1

1 reference

15 March 2018

Shuhei Nishiguchi

2

1 reference

15 March 2018

Keisuke Hino

3

1 reference

15 March 2018

Yoshihito Itoh

6

1 reference

15 March 2018

Yusuhiro Asahina

7

1 reference

15 March 2018

Akihiro Tamori

8

1 reference

15 March 2018

Naoki Hiramatsu

9

1 reference

15 March 2018

Norio Hayashi

10

1 reference

15 March 2018

publication date

1 April 2010

1 reference

15 March 2018

published in

Hepatology Research

1 reference

15 March 2018

volume

40

1 reference

15 March 2018

issue

4

1 reference

15 March 2018

page(s)

347-368

1 reference

15 March 2018

Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

45-year follow-up of hepatitis C virus infection in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2010.00642.X

Binding of hepatitis C virus to CD81

21 January 2018

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.282.5390.938

Identifiers

DOI

10.1111/J.1872-034X.2010.00642.X

1 reference

15 March 2018

PubMed ID

20394674

1 reference

15 March 2018